OncoMatch/Clinical Trials/NCT06386705
TSN084 Treating Patients With Advanced Malignant Tumors
Is NCT06386705 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TSN084 for malignant neoplasm.
Treatment: TSN084 — TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Allowed: MET exon 14 skipping mutation
Malignancies with targeted mutations are preferred, including but not limited to MET exon 14 skipping mutation and MET amplification.
Allowed: MET amplification
Malignancies with targeted mutations are preferred, including but not limited to MET exon 14 skipping mutation and MET amplification.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
adequate organ function at the time of screening
Kidney function
adequate organ function at the time of screening
Liver function
adequate organ function at the time of screening
Patients with adequate organ function at the time of screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify